BPH market to $5b
September 17, 2015
The global market for treatment
of benign prostatic hyperplasia
(BPH) is estimated to reach US$5b
by 2024 according to the latest data
from research and consulting firm
GlobalData.
Valued at just over US$2b in 2014
the data anticipates a compound
annual growth rate of 8.23%.
The latest data is based on the
seven major markets of the US,
France, Germany, Italy, Spain,
the UK and Japan with the US
accounting for 65% of the global
arena by 2024.
GlobalData’s director of
Cardiovascular & Metabolic
Disorders Valentina Gburcik states
that three novel therapies will
contribute to the growth of the
BPH therapeutics market, including
the launch of Nymox’s novel firstin-
class therapy, NX-1207 expected
in 2017-19.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Sep 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Sep 15